Stock Events

Stock Events

Eocene 

$4.09
0
+$0.00+0% Thursday 19:54
-$0.11-2.64%Thursday 23:36After hours

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Madrigal Pharmaceuticals
MDGL
Mkt Cap12.5B
Madrigal Pharmaceuticals is developing treatments for NASH, directly competing with Galmed's pipeline.
Viking Therapeutics
VKTX
Mkt Cap4.07B
Viking Therapeutics is working on treatments for metabolic and endocrine disorders, including NASH, making it a direct competitor.
Gilead Sciences
GILD
Mkt Cap187.23B
Gilead Sciences has a strong pipeline in liver disease treatments, including NASH, positioning it as a competitor.
Agios Pharmaceuticals
AGIO
Mkt Cap1.98B
Agios Pharmaceuticals, though primarily focused on cancer, has expanded into metabolic disorders, potentially competing in the NASH space.
Novartis
NVS
Mkt Cap304.1B
Novartis AG, a large pharmaceutical company, has interests in developing treatments for liver diseases, including NASH, making it a competitor.
Abbvie
ABBV
Mkt Cap453.19B
AbbVie Inc. has a diverse portfolio that includes research in liver diseases, potentially putting it in competition with Galmed.
Pfizer
PFE
Mkt Cap162.16B
Pfizer Inc. is involved in developing treatments for a wide range of conditions, including liver diseases, which could compete with Galmed's products.
Merck
MRK
Mkt Cap370.89B
Merck & Co., Inc. has a broad research portfolio that could include NASH treatments, positioning it as a potential competitor.

About

Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
Show more...
CEO
Allen Baharaff
Employees
6
Country
Israel
ISIN
IL0011313900

Listings

STU
DE
GPH.STU
F
DE
GPH.F
NASDAQ
US
EOCN
XNAS
US
GLMD

0 Comments

Share your thoughts

FAQ

What is Eocene stock price today?▼
The current price of EOCN is $4.09 USD — it has increased by +0% in the past 24 hours. Watch Eocene stock price performance more closely on the chart.
What is Eocene stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Eocene stocks are traded under the ticker EOCN.
How many employees does Eocene have?▼
As of September 11, 2026, the company has 6 employees.
In which sector is Eocene located?▼
Eocene operates in the Health & Wellness sector.
When did Eocene complete a stock split?▼
Eocene has not had any recent stock splits.
Where is Eocene headquartered?▼
Eocene is headquartered in Ramat Gan, Israel.